29 June 2020 Image: Robina Weermeijer Approval marks a significant step in GSK's global efforts to help patients with anaemia due to chronic kidney disease (CKD). GlaxoSmithKline has announced the approval of a Japanese New Drug Application (JNDA) by the Ministry of Health, Labour and Welfare for Duvroq (daprodustat) tablets, an oral hypoxia-inducible factor prolyl […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!